Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Sep. 30, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 85,366,448	$ 81,214,354
Trade receivable	75,000
Prepaid expenses	1,289,923	3,293,285
Other current assets	3,771,172	823,620
Short term investments		17,539,902
TOTAL CURRENT ASSETS	90,502,543	102,871,161
Property and equipment, net	15,386,761	4,526,848
Intangible assets, net	22,164,868	24,824,116
Other assets	122,333	45,789
TOTAL ASSETS	128,176,505	132,267,914
CURRENT LIABILITIES
Accounts payable	12,232,906	5,031,706
Accrued expenses	4,587,467	5,376,119
Accrued payroll and benefits	3,969,706	3,824,062
Deferred rent	440,580
Deferred revenue	2,569,792	103,125
Derivative liabilities	1,602,626	1,301,604
Capital lease obligation		217,548
Note Payable	194,310
Other current liabilities	46,407	46,407
TOTAL CURRENT LIABILITIES	25,643,794	15,900,571
LONG-TERM LIABILITIES
Capital lease obligation, net of current portion		540,792
Contingent consideration obligations	0	5,862,464
Deferred rent, net of current portion	2,274,997	142,453
Deferred revenue, net of current portion	2,500,000
Note Payable, net of current portion	2,533,455
Other non-current liabilities	200,000	200,000
TOTAL LONG-TERM LIABILITIES	7,508,452	6,745,709
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of September 30, 2016 and September 30, 2015	16	16
Common stock, $0.001 par value; 145,000,000 shares authorized; 69,746,685 and 59,544,677 shares issued and outstanding as of September 30, 2016 and September 30, 2015, respectively	162,116	151,914
Additional paid-in capital	493,844,909	426,873,358
Accumulated other comprehensive income (loss)	7,449	(136,425)
Accumulated deficit	(398,435,043)	(316,712,041)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	95,579,447	110,176,822
Noncontrolling interest	(555,188)	(555,188)
TOTAL STOCKHOLDERS’ EQUITY	95,024,259	109,621,634
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 128,176,505	$ 132,267,914

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.